BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Daratumumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Daratumumab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04973605-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT04973605)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Phase 1b/
 2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinati
 ons With Dexamethasone Plus Carfilzomib\, Dexamethasone Plus Daratumumab\,
  and Dexamethasone Plus Pomalidomide in Multiple Myeloma\nEstimated primar
 y completion: November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04973605
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06505369-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-
 cell Redirectors as Part of First Line Treatment in Transplant Eligible Mu
 ltiple Myeloma Patients\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Determine the Recommended Dose and Regimen and to Evaluate the Safety and 
 Preliminary Efficacy of CC-92480 in Combination With Standard Treatments i
 n Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and New
 ly Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 3989414
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04922723-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT04922723)
DESCRIPTION:Daratumumab\, phase 1/2.\nStudy: Radiation/Temozolomide and Imm
 unotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04922723
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04009109-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04009109)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Study of Lenalidomide/Ixazomib/D
 examethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diag
 nosed MM\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04009109
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05300451-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05300451)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Daratumumab in HLA Desensitizati
 on Prior to Transplantation\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05300451
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05888870-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Daratumumab: Phase 4 readout est. (NCT05888870)
DESCRIPTION:Daratumumab\, phase 4.\nStudy: ITI Using SCT800 Alone or Combin
 ing Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inh
 ibitor\nEstimated primary completion: 1 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05888870
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764861-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07764861)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Open-Label 
 Phase in Participants With Multiple Myeloma\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07764861
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697483-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Daratumumab: Phase na readout est. (NCT06697483)
DESCRIPTION:Daratumumab\, phase na\, Multiple Myeloma.\nStudy: Risk Stratif
 ication and MRD-driven Maintenance for MM After ASCT\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06697483
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270175-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04270175)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Daratumumab\, P
 omalidomide\, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain A
 myloidosis Patients Previously Exposed to Daratumumab\nEstimated primary c
 ompletion: January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04270175
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827860-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06827860)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Subcutaneous 
 Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06827860
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03829371-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270103
DTEND;VALUE=DATE:20270104
SUMMARY:Daratumumab: Phase 4 readout est. (NCT03829371)
DESCRIPTION:Daratumumab\, phase 4\, Multiple Myeloma.\nStudy: STUDY COMPARI
 NG TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGI
 BLE POPULATION AFFECTED BY MULTIPLE MYELOMA\nEstimated primary completion:
  3 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 tumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03829371
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268498-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04268498)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\, Carfilzomib\, Lenalidomide\, and Dexamethasone in Patients Wit
 h Newly-Diagnosed Multiple Myeloma\nEstimated primary completion: 1 Februa
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0426
 8498
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04133636-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04133636)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of JN
 J-68284528\, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed A
 gainst B-cell Maturation Antigen (BCMA) in Participants With Multiple Myel
 oma\nEstimated primary completion: 26 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04133636
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362199-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07362199)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Anti-CD38 Monoclonal Antibody Co
 mbined With Rituximab in the Management of Primary Immune Thrombocytopenia
  (ITP)\nEstimated primary completion: March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07362199
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04166565-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04166565)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab C
 ombined With Bortezomib\, Cyclophosphamide and Dexamethasone for the Treat
 ment of Multiple Myeloma Patients Presenting With Extramedullary Disease\n
 Estimated primary completion: March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04166565
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274462-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Daratumumab: Phase 4 readout est. (NCT07274462)
DESCRIPTION:Daratumumab\, phase 4.\nStudy: DARA-MVI Study (Daratumumab for 
 Microvascular Inflammation in Kidney Transplantation)\nEstimated primary c
 ompletion: 1 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07274462
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952478-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270309
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06952478)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Pharmacokinetics\, Efficacy and Safety of Subcutaneous CT-P44 and Da
 rzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patien
 ts With Refractory or Relapsed Multiple Myeloma\nEstimated primary complet
 ion: 8 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06952478
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363111-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270323
DTEND;VALUE=DATE:20270324
SUMMARY:Daratumumab: Phase 1 readout est. (NCT05363111)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: Radioimmunoth
 erapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relaps
 ed/Refractory Multiple Myeloma\nEstimated primary completion: 23 March 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05363111
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Ev
 aluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02343042-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT02343042)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: Selinexor a
 nd Backbone Treatments of Multiple Myeloma Patients\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT02343042
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04108195-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Daratumumab: Phase 1 readout est. (NCT04108195)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: A Study of Su
 bcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redi
 rection Antibodies for the Treatment of Participants With Multiple Myeloma
 \nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04108195
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622005-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:Daratumumab: Phase 1 readout est. (NCT06622005)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: SX-682 in Com
 bination With Carfilzomib\, Daratumumab-Hyaluronidase\, and Dexamethasone 
 in Patients With Relapsed or Refractory Multiple Myeloma\nEstimated primar
 y completion: 10 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06622005
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05849740-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Daratumumab: Phase 4 readout est. (NCT05849740)
DESCRIPTION:Daratumumab\, phase 4.\nStudy: An Exploratory Study of Cluster 
 of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid i
 n Acquired Hemophilia A\nEstimated primary completion: 30 April 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05849740
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04176718-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04176718)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\,
  Carfilzomib\, Pomalidomide\, Dexamethasone In MM\nEstimated primary compl
 etion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 tumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04176718
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721350-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daratumumab: Phase na readout est. (NCT07721350)
DESCRIPTION:Daratumumab\, phase na\, Multiple Myeloma.\nStudy: Prospective 
 Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDG
 E® Infusion System\nEstimated primary completion: May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07721350
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03346135-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03346135)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab A
 fter Stem Cell Transplant in Treating Patients With Multiple Myeloma\nEsti
 mated primary completion: 17 May 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03346135
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788456-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Daratumumab: Phase 4 readout est. (NCT07788456)
DESCRIPTION:Daratumumab\, phase 4.\nStudy: Multi-target Drugs Sequential Co
 mbination Therapy in Adults Patients With Newly Diagnosed Primary Immune T
 hrombocytopenia\nEstimated primary completion: 30 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07788456
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015724-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06015724)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Anti-CD38 Antibody With KRAS Vac
 cine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcin
 oma and Refractory Non-Small Cell Lung Cancer\nEstimated primary completio
 n: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratum
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06015724
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889948-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06889948)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: The Effect of Daratumumab in Pat
 ients With Monoclonal Gammopathy of Renal Significance (MGRS) in Finland\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06889948
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05572229-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05572229)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Study of Tecl
 istamab in Combination in Elderly Patients With Multiple Myeloma\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05572229
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191379-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270629
DTEND;VALUE=DATE:20270630
SUMMARY:Daratumumab: Phase 4 readout est. (NCT07191379)
DESCRIPTION:Daratumumab\, phase 4\, Multiple Myeloma.\nStudy: Self-administ
 ered Subcutaneous Daratumumab in Patients With Multiple Myeloma\nEstimated
  primary completion: 29 June 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07191379
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289687-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05289687)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Daratumumab for Chemotherapy-Ref
 ractory Minimal Residual Disease in T Cell ALL\nEstimated primary completi
 on: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dar
 atumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05289687
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556332-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03556332)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Ca
 rfilzomib\, Lenalidomide\, Dexamethasone and Daratumumab for Patients With
  Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Tr
 ansplantation\nEstimated primary completion: July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03556332
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04124497-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04124497)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Trial for R
 elapsed and Relapsed/Refractory Multiple Myeloma Patients\nEstimated prima
 ry completion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04124497
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04915248-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04915248)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Study to Evaluate Combined Treat
 ment of Daratumumab\, Bortezomib and Dexamethasone in PBL Patients.\nEstim
 ated primary completion: 1 July 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04915248
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05455320-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05455320)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Talquetamab in Combination With Daratumumab or in Combination With Da
 ratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalido
 mide and Dexamethasone in Participants With Multiple Myeloma That Returns 
 After Treatment or is Resistant to Treatment\nEstimated primary completion
 : 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/darat
 umumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05455320
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04497961-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04497961)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of He
 alth-Related Quality of Life in People With Multiple Myeloma Receiving Dar
 atumumab or Lenalidomide\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04497961
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04972942-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Daratumumab: Phase 1 readout est. (NCT04972942)
DESCRIPTION:Daratumumab\, phase 1.\nStudy: Targeted Immunotherapy After Mye
 loablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell 
 ALL & Lymphoma\nEstimated primary completion: September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04972942
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06398457-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Daratumumab: Phase 1 readout est. (NCT06398457)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: Darzalex Fasp
 ro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization an
 d Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in 
 Adult Patients at High-risk for Primary Graft Failure Secondary to Donor S
 pecific Antibodies\nEstimated primary completion: September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06398457
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04635189-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20270908
DTEND;VALUE=DATE:20270909
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04635189)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Steroid Spari
 ng Treatment With in Newly Diagnosed Transplant Ineligible Patients With M
 ultiple Myeloma\nEstimated primary completion: 8 September 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04635189
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A St
 udy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03763162-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03763162)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Daratumumab\,
  Bortezomib\, and Dexamethasone Followed by Daratumumab\, Ixazomib\, and D
 examethasone in Treating Patients With Relapsed or Refractory Multiple Mye
 loma\nEstimated primary completion: 30 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03763162
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297563-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07297563)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Anti-CD38 Monoclonal Antibody Ve
 rsus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)\
 nEstimated primary completion: November 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07297563
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07018050)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Phase II Stud
 y of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEs
 timated primary completion: November 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142396-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Daratumumab: Phase 1 readout est. (NCT06142396)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: Pilot Study D
 ara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
 \nEstimated primary completion: 1 November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06142396
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04975997-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271116
DTEND;VALUE=DATE:20271117
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04975997)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Open-label St
 udy Comparing Iberdomide\, Daratumumab and Dexamethasone (IberDd) Versus D
 aratumumab\, Bortezomib\, and Dexamethasone (DVd) in Participants With Rel
 apsed or Refractory Multiple Myeloma (RRMM)\nEstimated primary completion:
  16 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04975997
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409702-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Daratumumab: Phase 4 readout est. (NCT06409702)
DESCRIPTION:Daratumumab\, phase 4\, Multiple Myeloma.\nStudy: Treatment of 
 High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease D
 etection\nEstimated primary completion: 30 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06409702
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04775550-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271220
DTEND;VALUE=DATE:20271221
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04775550)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: DARA RVD For 
 High Risk SMM\nEstimated primary completion: 20 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04775550
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06615479-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06615479)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Ad
 ult Participants With Relapsed or Refractory and Lenalidomide-exposed Mult
 iple Myeloma (QUINTESSENTIAL-2)\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066154
 79
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287228-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07287228)
DESCRIPTION:Daratumumab\, phase 1/2.\nStudy: The Safety and Efficacy of Dar
 atumumab in Patients With Refractory Aplastic Anemia\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07287228
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107738-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06107738)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide an
 d Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transpl
 ant for Multiple Myeloma\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06107738
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335887-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07335887)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Sonrotoclax Plu
 s Dexamethasone With or Without Daratumumab Regimen in Patients With t(11\
 ;14) Primary AL Amyloidosis\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07335887
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902609-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07902609)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Sequential Daratumumab Followed 
 by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A P
 hase IIa Clinical Trial\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07902609
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566328-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04566328)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Testing the U
 se of Combination Therapy in Adult Patients With Newly Diagnosed Multiple 
 Myeloma\, the EQUATE Trial\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04566328
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04661137-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Daratumumab: Phase 2 readout est. (NCT04661137)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Se
 linexor\, in Combination With Carfilzomib\, Daratumumab or Pomalidomide in
  Patients With Multiple Myeloma\nEstimated primary completion: February 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04661137
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743957-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07743957)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Selinexor\, Daratumumab\, and De
 xamethasone (XDd) for Light-Chain Cardiac Amyloidosis\nEstimated primary c
 ompletion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07743957
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948084-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06948084)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Testing the I
 nvestigational Medication Combination of Daratumumab and Teclistamab Compa
 red to the Usual Treatment (Daratumumab\, Pomalidomide\, Dexamethasone or 
 Daratumumab\, Carfilzomib\, Dexamethasone) for Patients With High-risk Mul
 tiple Myeloma Refractory or in First Relapse\nEstimated primary completion
 : 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06948084
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221032-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Daratumumab: Phase 1 readout est. (NCT07221032)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: FT836 CAR T-c
 ell Therapy in Combination With Daratumumab in Patients With Relapsed and/
 or Refractory Multiple Myeloma\nEstimated primary completion: March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07221032
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362238-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07362238)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Daratumumab Versus Rituximab in 
 the Management of Pediatric Primary Immune Thrombocytopenia (ITP)\nEstimat
 ed primary completion: March 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07362238
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Daratumumab: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: A Study to Ex
 amine the Effects of Novel Therapy Linvoseltamab in Combination With Other
  Cancer Treatments for Adult Participants With Multiple Myeloma That is Re
 sistant to Current Standard of Care Treatments\nEstimated primary completi
 on: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05137054
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341867-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Daratumumab: Phase 1 readout est. (NCT07341867)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: Systemic Anti
 -Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenoty
 pe\nEstimated primary completion: 31 March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07341867
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045909-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07045909)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Efficacy and 
 Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed M
 ultiple Myeloma (GEM-AnitoFIRST)\nEstimated primary completion: 31 March 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07045909
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resid
 ual Disease-based Strategy With T-Cell Redirector After Treatment With Dar
 atumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485647-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07485647)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Identifying E
 ffective and Cost-Conscious Maintenance Daratumumab Dosing\nEstimated prim
 ary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07485647
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671757-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280505
DTEND;VALUE=DATE:20280506
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT05671757)
DESCRIPTION:Daratumumab\, phase 1/2.\nStudy: Daratumumab in Primary Antipho
 spholipid Syndrome\nEstimated primary completion: 5 May 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05671757
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742215-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07742215)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of th
 e Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patien
 ts With Relapsed or Refractory Multiple Myeloma (AMMADINA)\nEstimated prim
 ary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07742215
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638683-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07638683)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Phase II St
 udy to Evaluate the Efficacy and Safety of Teclistamab in Combination With
  Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurren
 t Light Chain Amyloidosis (MM+AL).\nEstimated primary completion: 30 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763868
 3
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05434689-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT05434689)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: COMbination
  Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide\nEstimated
  primary completion: August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05434689
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05654506-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05654506)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Daratumumab for Treatment of Pro
 liferative Glomerulonephritis With Monoclonal Immune Deposits\nEstimated p
 rimary completion: August 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05654506
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749276-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280806
DTEND;VALUE=DATE:20280807
SUMMARY:Daratumumab: Phase 1 readout est. (NCT05749276)
DESCRIPTION:Daratumumab\, phase 1.\nStudy: Escalation of Doses of Daratumum
 ab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351)
  in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic 
 Leukemia (AML) (DARALAM)\nEstimated primary completion: 6 August 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05749276
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231629-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05231629)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Sequential Th
 erapy in Multiple Myeloma Guided by MRD Assessments\nEstimated primary com
 pletion: September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05231629
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / D
 SMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratum
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05695508
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110662-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281029
DTEND;VALUE=DATE:20281030
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07110662)
DESCRIPTION:Daratumumab\, phase 1/2.\nStudy: New Therapeutic Target for Tox
 ic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.\nEst
 imated primary completion: 29 October 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07110662
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234019-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07234019)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Rituximab Combining Anti-CD38 Mo
 noclonal Antibody Versus Rituximab in the Management of Primary Immune Thr
 ombocytopenia (ITP)\nEstimated primary completion: November 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07234019
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910568-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Daratumumab: Phase 1 readout est. (NCT04910568)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: A Study Evalu
 ating the Safety\, Pharmacokinetics\, and Activity of Cevostamab in Partic
 ipants With Relapsed or Refractory Multiple Myeloma\nEstimated primary com
 pletion: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04910568
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100237-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06100237)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinica
 l and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06100237
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06768489-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Daratumumab: Phase 1 readout est. (NCT06768489)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: A Study of Ra
 mantamig in Combination With Daratumumab With or Without Lenalidomide or o
 f Single-agent JNJ-102299639 for Multiple Myeloma\, Newly Diagnosed AL Amy
 loidosis\, and High-risk Smoldering Multiple Myeloma or Ramantamig in Comb
 ination With Pomalidomide for Multiple Myeloma\nEstimated primary completi
 on: 2 January 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06768489
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636552-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290105
DTEND;VALUE=DATE:20290106
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06636552)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: An Investigator-Initiated\, Phas
 e II\, Multicenter\, Open-Label\, Single-Arm\, Prospective Clinical Trial 
 to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regime
 ns in Combination With DaratUMumab Followed by Maintenance With Daratumuma
 b in the Frontline Setting of Primary Plasma CEll L\nEstimated primary com
 pletion: 5 January 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06636552
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085728-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07085728)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Testing the I
 nvestigational Agent Combination of Daratumumab\, Bortezomib\, and Dexamet
 hasone Compared to the Usual Treatment of Cyclophosphamide\, Bortezomib\, 
 and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney
  Failure\nEstimated primary completion: 11 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07085728
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07764978)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD0
 120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated pri
 mary completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07764978
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05438043-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05438043)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\nEstimated primary completion: 31 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05438043
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896228-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05896228)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide\, 
 Daratumumab\, Carfilzomib\, and Dexamethasone (Iber-KDd) in Patients With 
 Relapsed/Refractory Multiple Myeloma\nEstimated primary completion: 1 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05896
 228
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107529-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07107529)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Study for Fra
 il Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab
  With Teclistamab or Talquetamab.\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07107529
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830485-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290415
DTEND;VALUE=DATE:20290416
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07830485)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: CM336 Plus Da
 ratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multip
 le Myeloma\nEstimated primary completion: 15 April 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07830485
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891923-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290505
DTEND;VALUE=DATE:20290506
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07891923)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Less Doses of
  Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple 
 Myeloma\nEstimated primary completion: 5 May 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07891923
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287944-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290519
DTEND;VALUE=DATE:20290520
SUMMARY:Daratumumab: Phase 1 readout est. (NCT06287944)
DESCRIPTION:Daratumumab\, phase 1.\nStudy: 225Ac-DOTA-Anti-CD38 Daratumumab
  Monoclonal Antibody With Fludarabine\, Melphalan and Total Marrow and Lym
 phoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant
  in Patients With High-Risk Acute Myeloid Leukemia\, Acute Lymphoblastic L
 eukemia and Myelodysplastic Syndrome\nEstimated primary completion: 19 May
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062879
 44
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222761-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290521
DTEND;VALUE=DATE:20290522
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07222761)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Co
 mpare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combinatio
 n Therapy With Standard-of-Care Combination Regimens in Adult Participants
  With Relapsed/Refractory Multiple Myeloma (RRMM)\nEstimated primary compl
 etion: 21 May 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07222761
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04139304-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Daratumumab: Phase 1 readout est. (NCT04139304)
DESCRIPTION:Daratumumab\, phase 1.\nStudy: A Study of Daratumumab and Dose-
 Adjusted EPOCH in Plasmablastic Lymphoma\nEstimated primary completion: Ju
 ly 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0413
 9304
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07099391-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290724
DTEND;VALUE=DATE:20290725
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07099391)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study of 
 Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma\nEstimated pr
 imary completion: 24 July 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07099391
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstima
 ted primary completion: 25 August 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253637-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06253637)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Daratumumab in VHR T-ALL Treated
  According to the ALL National Treatment Program\nEstimated primary comple
 tion: October 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06253637
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05898646-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05898646)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Daratumumab Mai
 ntenance Therapy for Improving Survival in Patients With Light Chain Amylo
 idosis\, EMILIA Trial\nEstimated primary completion: 30 November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05898646
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05527340-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05527340)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Iberdomide-de
 xamethasone Alone or in Combination With Standard MM Treatment Regimens in
  Transplant Ineligible Newly Diagnosed Patients.\nEstimated primary comple
 tion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05527340
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513129-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Daratumumab: Phase 1 readout est. (NCT07513129)
DESCRIPTION:Daratumumab\, phase 1.\nStudy: Venetoclax\, Dexamethasone\, Bor
 tezomib\, and Daratumumab For The Treatment Of Adolescent And Young Adults
  With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cel
 l Acute Lymphoblastic Lymphoma\nEstimated primary completion: 31 December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0751312
 9
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937635-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT03937635)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Lenalidomide\
 , and Dexamethasone With or Without Daratumumab in Treating Patients With 
 High-Risk Smoldering Myeloma\nEstimated primary completion: 31 December 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03937635
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immune
  HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimated
  primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06022939-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300729
DTEND;VALUE=DATE:20300730
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06022939)
DESCRIPTION:Daratumumab\, phase 3\, AL Amyloidosis.\nStudy: Comparing Dara-
 VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone 
 for People Who Have Newly Diagnosed AL Amyloidosis\nEstimated primary comp
 letion: 29 July 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06022939
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665450-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20300904
DTEND;VALUE=DATE:20300905
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07665450)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Ra
 mantamig Plus Daratumumab Versus Daratumumab\, Bortezomib\, Lenalidomide\,
  and Dexamethasone (DVRd) or Daratumumab\, Lenalidomide\, and Dexamethason
 e (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Pla
 nned\nEstimated primary completion: 4 September 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07665450
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075510-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07075510)
DESCRIPTION:Daratumumab\, phase 1/2.\nStudy: Subcutaneous Daratumumab Admin
 istration in the Thigh Vs Abdomen in Plasma Cell Disorders\nEstimated prim
 ary completion: 1 October 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07075510
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05623020-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05623020)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn About the Effects of the Combination of Elranatamab\, Daratumumab and 
 Lenalidomide Compared With Daratumumab\, Bortezomib\, Lenalidomide\, and D
 examethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not
  Candidates for Transplant\nEstimated primary completion: 18 October 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05623020
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax A
 lone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in
  Adult Participants With Multiple Myeloma (MM)\nEstimated primary completi
 on: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 ratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06953960
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247097-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07247097)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: ELDORADO: Elr
 anatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnos
 ed Transplant Ineligible/Deferred Multiple Myeloma\nEstimated primary comp
 letion: 1 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07247097
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06187441-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06187441)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: FeAsiBility o
 f a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Da
 ratumumab-lenalidomide-dexamethasone (HOVON174MM)\nEstimated primary compl
 etion: January 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06187441
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671287-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310214
DTEND;VALUE=DATE:20310215
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07671287)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: GMMG-HD11/DSM
 M XXI/64007957MMY3010\nEstimated primary completion: 14 February 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07671287
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681596-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310306
DTEND;VALUE=DATE:20310307
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT07681596)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Modular\,
  Phase I/II\, Multicentre Study to Evaluate AZD4045\, in Participants With
  Relapsed or Refractory Multiple Myeloma\nEstimated primary completion: 6 
 March 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7681596
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06785415-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310401
DTEND;VALUE=DATE:20310402
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT06785415)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: Elotuzumab\
 , Daratumumab\, Iberdomide\, and Dexamethasone for the Treatment of Relaps
 ed Multiple Myeloma\nEstimated primary completion: 1 April 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06785415
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 aratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Daratumumab: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Co
 mbination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With an
 d Without Bortezomib) in Participants With Relapsed or Refractory Multiple
  Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05561387-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310530
DTEND;VALUE=DATE:20310531
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05561387)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Comparing Com
 binations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a
  Stem Cell Transplant is Not a Medically Suitable Treatment\nEstimated pri
 mary completion: 30 May 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05561387
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04513639-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20310601
DTEND;VALUE=DATE:20310602
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT04513639)
DESCRIPTION:Daratumumab\, phase 2/3\, Multiple Myeloma.\nStudy: The Relapse
  from MRD Negativity As Indication for Treatment (REMNANT) Study\nEstimate
 d primary completion: 1 June 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04513639
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110844-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07110844)
DESCRIPTION:Daratumumab\, phase 2\, AL Amyloidosis.\nStudy: Teclistamab-Dar
 atumumab in AL Amyloidosis\nEstimated primary completion: October 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07110844
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04071457-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Daratumumab: Phase 3 readout est. (NCT04071457)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: S1803\, Lenal
 idomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to D
 irect Therapy Duration\nEstimated primary completion: September 2032. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04071457
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06574126-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06574126)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Ciltacabtagen
 e Autoleucel in High-Risk Smoldering Multiple Myeloma\nEstimated primary c
 ompletion: 30 September 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06574126
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06974786-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06974786)
DESCRIPTION:Daratumumab\, phase 2\, Multiple Myeloma.\nStudy: Frontline T-c
 ell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Resid
 ual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple My
 eloma\nEstimated primary completion: November 2032. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06974786
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605416-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20321106
DTEND;VALUE=DATE:20321107
SUMMARY:Daratumumab: Phase 2 readout est. (NCT07605416)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Testing an Experimental Approach
  to Treat Patients With Plasma Cell Leukemia\, The QUANTUM Trial\nEstimate
 d primary completion: 6 November 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07605416
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257083-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Daratumumab: Phase 3 readout est. (NCT05257083)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Da
 ratumumab\, Bortezomib\, Lenalidomide and Dexamethasone (DVRd) Followed by
  Ciltacabtagene Autoleucel Versus Daratumumab\, Bortezomib\, Lenalidomide 
 and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT
 ) in Participants With Newly Diagnosed Multiple Myeloma\nEstimated primary
  completion: June 2033. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05257083
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Personalising
  Treatment for Myeloma Patients Based on Initial Response to NHS Treatment
  and Their Overall Fitness Level\nEstimated primary completion: June 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Daratumumab\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing B
 ispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly 
 Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 
 1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratu
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07887984
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05259839-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:Daratumumab: Phase 1 readout est. (NCT05259839)
DESCRIPTION:Daratumumab\, phase 1\, Multiple Myeloma.\nStudy: A Study to As
 sess Adverse Events and Change in Disease Activity of Intravenously (IV) I
 nfused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for t
 he Treatment of Adult Participants With Relapsed/Refractory Multiple Myelo
 ma\nEstimated primary completion: September 2033. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05259839
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05907759-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20340801
DTEND;VALUE=DATE:20340802
SUMMARY:Daratumumab: Phase 2 readout est. (NCT05907759)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Daratumumab for Relapsed/Refract
 ory Primary Effusion Lymphoma\, Plasmablastic Lymphoma\, and Multicentric 
 Castleman Disease\nEstimated primary completion: 1 August 2034. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05907759
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072585-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20350901
DTEND;VALUE=DATE:20350902
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT07072585)
DESCRIPTION:Daratumumab\, phase 2/3.\nStudy: Testing the Addition of Daratu
 mumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Ly
 mphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)\nEst
 imated primary completion: 1 September 2035. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07072585
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Daratumumab: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Daratumumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Change in Disease Activity and Adverse Events (AE)s in Adult Partic
 ipants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Ant
 ibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nE
 stimated primary completion: December 2035. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918002-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20360531
DTEND;VALUE=DATE:20360601
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06918002)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: Elranatamab/L
 enalidomide Consolidation and/or Elranatamab Maintenance Versus Standard o
 f Care After D-VRd Induction in Transplant-eligible NDMM Patients\nEstimat
 ed primary completion: May 2036. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daratumumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06918002
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06932562-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Daratumumab: Phase 3 readout est. (NCT06932562)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Study to Le
 arn How Safe and How Well Linvoseltamab Works Compared to Standard Treatme
 nt in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transp
 lant\nEstimated primary completion: December 2036. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06932562
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903272-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20370111
DTEND;VALUE=DATE:20370112
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07903272)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Trial Compa
 ring Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab\, Bortez
 omib\, Lenalidomide\, and Dexamethasone in Participants With Newly Diagnos
 ed Multiple Myeloma Who Are Transplant Eligible\nEstimated primary complet
 ion: 11 January 2037. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /daratumumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07903272
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095452-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20410331
DTEND;VALUE=DATE:20410401
SUMMARY:Daratumumab: Phase 2/3 readout est. (NCT07095452)
DESCRIPTION:Daratumumab\, phase 2/3\, Multiple Myeloma.\nStudy: A Study to 
 Assess A Change in Disease Activity and Adverse Events of Intravenous Eten
 tamig and Daratumumab (Etentamig+D) Compared to Daratumumab\, Lenalidomide
 \, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Mult
 iple Myeloma Not Eligible for Transplant\nEstimated primary completion: Ma
 rch 2041. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratumumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070
 95452
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887672-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20420228
DTEND;VALUE=DATE:20420301
SUMMARY:Daratumumab: Phase 3 readout est. (NCT07887672)
DESCRIPTION:Daratumumab\, phase 3\, Multiple Myeloma.\nStudy: A Trial to Ev
 aluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of
  Care in Newly Diagnosed Multiple Myeloma\nEstimated primary completion: F
 ebruary 2042. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daratum
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07887672
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06358638-2289@assetmemo.bio
DTSTAMP:20261121T005633Z
DTSTART;VALUE=DATE:20440930
DTEND;VALUE=DATE:20441001
SUMMARY:Daratumumab: Phase 2 readout est. (NCT06358638)
DESCRIPTION:Daratumumab\, phase 2.\nStudy: Sickle Cell Disease Transplant U
 sing a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Ant
 ibody\nEstimated primary completion: September 2044. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daratumumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06358638
URL:https://assetmemo.bio/drug/daratumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
